Figure 4.

Specific response to chemotherapy in CRC subtypes. (a) Heatmap showing individual responses of patients with primary CRC (Del Rio data set³⁴, n = 21) to FOLFIRI treatment and their association with subtypes. The subtypes in the Del Rio data set were identified after merging the data set with the core CRC data sets (Supplementary Fig. 8c). Complete and partial responses and stable disease were considered as beneficial response, whereas progressive disease was deemed as no response. (b,c) Heatmaps showing association of individual patient CRC responses in the Khambata-Ford data set (metastases) (b) and in the core data sets (includes samples from all of the Dukes’ stages) (c) to FOLFIRI by applying published FOLFIRI response signatures³⁵ using the NTP algorithm. In these analyses, statistics include only those samples that were predicted with FDR < 0.2. (d) CRC subtype–specific cell line response to FOLFIRI components. Namely, the combination of 5-FU (239 µM) and irinotecan (22.5 µM), plotted as percentage cellular proliferation and normalized to vehicle-treated cells. Error bars represent the s.d. of technical replicates from a representative experiment. *P < 0.05. TA, transit amplifying.